EA: Eventos adversos.
Referencias: 1. Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory medicine. 2019;150:51-62. 2. Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1-16. 3. Nagase H, Suzukawa M, Oishi K, et al. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergology International. 2023;72(1):11-23. 4. Sitek AN, Li JT, Pongdee T. Risks and safety of biologics: A practical guide for allergists. World Allergy Organization Journal. 2023;16(1):100737. 5. Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431-44.

Material exclusivo para el profesional de la salud.

Las imágenes no corresponden a pacientes o profesionales de la salud reales.

No. de Reg. 251M2006 SSA IV     Content ID: FA-11355768     Fecha de vigencia: 23/10/26     No. de Aviso: 2509052002C00136